The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise.
Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus
Paul Tunnah sat down with Livongo’s CEO Zane Burke to discuss how he has applied lessons from bigger companies in his new role and his thoughts on health tech’s relationship with patients a
Novo Nordisk’s Ozempic (semaglutide) weekly GLP-1 injection has gained a new US indication after the FDA agreed a label extension to cover reducing the risk of cardiac events in adults with
Swiss digital therapy specialist Oviva has raised $21 million in second-round financing to help expand the use of smartphone-based tools designed to help people with diabetes manage their c
Researchers from a UK university have devised an artificial intelligence (AI)-based system that can detect low glucose levels using an ECG readout without a fingerprick test, in healthy pat